Literature DB >> 21383680

Aprepitant (Emend) significantly increases sirolimus levels in patients undergoing allogeneic hematopoietic SCT.

S Shayani, J M Palmer, T Stiller, H Chan, S Keuylian, P Parker, S Thomas, V Pullarkat, A Nademanee, S J Forman, R Nakamura.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21383680     DOI： 10.1038/bmt.2011.42

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  3 in total

Review 1.  Aprepitant and fosaprepitant drug interactions: a systematic review.

Authors:  Priya Patel; J Steven Leeder; Micheline Piquette-Miller; L Lee Dupuis
Journal:  Br J Clin Pharmacol       Date:  2017-06-10       Impact factor: 4.335

Review 2.  Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.

Authors:  Jeannine S McCune; Meagan J Bemer; Janel Long-Boyle
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

3.  Relationship between CYP3A5 Polymorphism and Tacrolimus Blood Concentration Changes in Allogeneic Hematopoietic Stem Cell Transplant Recipients during Continuous Infusion.

Authors:  Naoki Yoshikawa; Hidemi Takeshima; Masaaki Sekine; Keiichi Akizuki; Tomonori Hidaka; Kazuya Shimoda; Ryuji Ikeda
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.